Eurand N.V. company was formerly known as Eurand B.V. Eurand N.V. was incorporated in 1984 and is based in Amsterdam, the Netherlands. Eurand N.V., a specialty pharmaceutical company, develops, manufactures, and commercializes pharmaceutical and biopharmaceutical products. The company develops these products based on its proprietary customized release technologies used to reduce daily dosing requirements and time the release of drugs in the body to increase efficacy or to reduce side effects; Tastemasking/ODTs technologies to increase patient compliance through more convenient dosage forms, such as orally disintegrating tablets and taste-masked drugs; bioavailability enhancement technologies to improve drug absorption; and drug conjugation technologies to extend drug half-life and to target specific organs or other biological targets, such as tumors. Its technologies are used for applications in drug products used for various therapeutic areas, including cardiovascular, gastrointestinal, pain, nutrition, and respiratory.Eurand company offers EUR-1037, as an over-the-counter sleep-aid; EUR-1025, an oral formulation of ondansetron, an anti-emetic prescribed to prevent nausea and vomiting; and EUR-1073, an enteric coated, controlled release formulation of beclomethasone diproprionate for the treatment of inflammatory bowel disease. It products also include Zentase, also known as EUR-1008, a porcine-derived proprietary enzyme replacement product for the treatment of exocrine pancreatic insufficiency, which has completed Phase III clinical trials; Amrix, a sustained release formulation of cyclobenzaprine hydrochloride, used as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute and painful musculoskeletal conditions; and products and services to the cystic fibrosis community.

Clinical Data, Inc. company was founded in 1969 and is headquartered in Newton, Massachusetts. Clinical Data, Inc. operates as a global biotechnology company developing early and late stage targeted therapeutics, as well as genetic and pharmacogenomic tests that detect serious diseases and help predict drug safety, tolerability, and efficacy. Its late-stage compounds include Vilazodone, a potential drug candidate for the treatment of depression, and Stedivaze, a potential cardiac stress agent. The company employs biomarker strategies and technologies to develop targeted therapeutics with advantages over existing treatments to help patients, healthcare professionals, and payers. Its PGxHealth division is leveraging its biomarker discovery expertise and intellectual property to develop and commercialize pharmacogenomic tests to detect serious diseases and help predict drug safety, tolerability, and efficacy. PGxHealth built the commercial, managed care, and CLIA-certified laboratory infrastructure and capabilities to support its marketed tests, including the FAMILION family of genetic tests for inherited heart diseases and PGxPredict tests for predicting drug response. The company has a collaboration and licensing agreement with CombinatoRx Inc. to develop an adenosine A2A agonist compound in a combination therapy for the treatment of multiple myeloma and other B-cell cancers.

Zeltia SA is a Spain-based holding company primarily engaged, through its subsidiaries, in the chemical and pharmaceutical sectors. Its main subsidiaries are: PharmaMar SA, biopharmaceutical company committed to advancing the treatment of cancer; Noscira SA, engaged in the research and development of innovative drugs for diseases of the nervous system; Genomica SAU, specializes in molecular diagnosis; Sylentis SAU, focused on the discovering and developing new therapeutic approaches based on gene silencing techniques; Zelnova SA, which produces and markets cleaning products for household and cetring sectors; and Xylazel SA, producer of paints, varnishes, wood and metal protectors for the industrial sector.

The Micron Group delves deeply into the world of drug discovery. Composed of companies based in the UK, the US, and South Africa -- including Micron Research, the group's flagship unit -- the group provides consulting services for pharmaceuticals research, development, and delivery companies. With expertise in Phase I-IV drug discovery trials, clinical research, data delivery, medical education, and medical communications, the group's services range from clinical development and research to marketing, strategic planning, and report publishing. The Micron Group also offers its SILK software for managing pharmaceutical R&D and marketing processes. Clients include Bristol-Myers Squibb and the World Health Organization.

Evotec AG (Evotec) is a drug discovery and development company focused on small molecule therapeutics. Evotec is developing treatments for diseases in the areas of neuroscience, pain, and inflammation. Evotec’s portfolio comprises five clinical drug candidates: EVT 101, a subtype selective NMDA receptor antagonist with potential for the treatment of Alzheimer’s disease, pain and depression, EVT 201, a partial positive allosteric modulator (pPAM) of the GABAA receptor complex for the treatment of insomnia, EVT 302, a MAO-B inhibitor in development for smoking cessation, a P2X7 antagonist for the treatment of inflammatory diseases, and a small molecule vanilloid receptor (VR1) antagonist for the treatment of pain in partnership with Pfizer. Evotec’s late stage preclinical research programs focus on EVT 103, a back-up compound to EVT 101, H3 antagonists for the treatment of cognitive disorders and/or sleep, as well as antagonists for the purinergic receptor P2X3 for the treatment of pain.

Martek Biosciences Corporation was founded in 1985 and is headquartered in Columbia, Maryland. Martek Biosciences Corporation engages in the innovation and development of nutritional products from microbial sources, including algae, fungi, and other microbes worldwide. Its products include life'sDHA, a vegetarian source of the omega-3 fatty acid DHA (docosahexaenoic acid) for use in infant formula, pregnancy and nursing products, foods and beverages, dietary supplements, and animal feeds; and life'sARA, a vegetarian source of the omega-6 fatty acid ARA (arachidonic acid) for use in infant formula. The company also provides contract manufacturing services for the production of enzymes, specialty chemicals, vitamins, and agricultural specialty products. It sells oils containing fatty acids under the names of life'sDHA, DHASCO, Neuromins, ARASCO, and life'sARA. The company markets its nutritional oils primarily to the infant formula, pregnancy and nursing, food and beverage, dietary supplement, and animal feed markets.

DRAXIS Specialty Pharmaceuticals (formerly DRAXIS Health) lights up your insides with its own radiopharmaceuticals, but its main business is making other drug companies' injectable drugs, lotions and pills. The company's larger DRAXIS Pharma unit is a contract manufacturer specializing in liquid and freeze-dried injectable drugs, though it also makes sterile and non-sterile ointments, creams, and other formulations. Another unit, DRAXIMAGE, develops and makes radiopharmaceuticals, such as radioactive iodine, for use in diagnostic and therapeutic nuclear medicine procedures. DRAXIMAGE sells its products mostly in the US and Canada. In 2008 India-based Jubilant Organosys acquired DRAXIS for about $255 million.

Orexigen Therapeutics was founded in 2002 and is headquartered in La Jolla, California. Orexigen Therapeutics, Inc., a biopharmaceutical company, focusing on the development of pharmaceutical product candidates for the treatment of obesity. Orexigen Therapeutics's lead combination product candidates targeted for obesity are Contrave, which is in Phase III clinical trials, and Empatic, which is in the later stages of Phase II clinical development. It selected these two product candidates for obesity based research regarding CNS regulation of appetite and energy expenditure, as well as mechanisms in the brain that reinforce unhealthy eating behaviors. Each of these product candidates is a combination of generic drugs that is screened for synergistic CNS activity.

Spectrum Laboratories is wrapped up in a full gamut of filtration products. Spectrum operates three product groups: bioprocessing (membranes, membrane devices, diagnostics, and pharmaceuticals), Original Equipment Manufacturing (or "OEM", which supplies filtration and separation devices to companies making in vivo and ex-vivo filtration devices), and disposable operating room products (orthopedic and arthroscopic drapes, sterile microscope covers, tissue carriers, and other disposables). Spectrum also does contract manufacturing to create customized products with filtration applications for laboratory use. It has three production facilities in the US along with sales offices in the Netherlands and Japan.

Galderma Laboratories, L.P., a dermatology company, engages in the research, development, and marketing of dermatology products. Its pharmaceutical and over-the-counter products include Differin, which is used to treat acne; MetroGel, MetroLotion, and MetroCream, to treat rosacea; Clobex lotion, which helps in controlling and treating moderate-to-severe plaque psoriasis; and Cetaphil, a line of cleansers and moisturizers. The company has operations in North America, Western Europe, Latin America, Asia, Australia, and Africa. It offers its services directly, and through sales representatives, as well as through special programs. The company was founded in 1961 as Owen Laboratories and changed its name to Galderma Laboratories, L.P. in 1981. The company is headquartered in Fort Worth, Texas. Galderma Laboratories, L.P. operates as a subsidiary of Galderma SA.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.